Table 2.
Monoclonal antibodies and their reactivity to RBD by subject
| Subject ID | Plasma characteristics |
mAb characterstics |
Neutralizing mAbs |
|||||
|---|---|---|---|---|---|---|---|---|
| DPS | RBD titer | IgG derived | IgD derived | RBD binding | Neutralizing | IGHV usage | SHM (%) | |
| 61250-011 | 68 | 1,857.63 | 4 | 0 | 4 | 1 | ||
| 181 | 491.67 | 20 | 0 | 20 | 5 | 3–33, 1–58 | 6, 7 | |
| 61213-007 | 132 | 0 | 15 | 0 | 15 | 6 | 4–31, 1–2 | 2, 5 |
| 61250-002 | 110 | 493.95 | 9 | 0 | 9 | 2 | 3–66, 4–39 | 5, 7 |
| 61213-016 | 137 | 12.24 | 1 | 12 | 2 | 0 | – | – |
| 61247-024 | 118 | 0 | 0 | 15 | 0 | 0 | – | – |
DPS, days post-onset of symptoms; IgD, immunoglobulin D; IgG, immunoglobulin G; mAb, monoclonal antibody; RBD, receptor-binding domain; SHM, somatic hypermutation.